VU 0357121
CAS No. 433967-28-3
VU 0357121 ( VU-0357121, VU0357121, VU 0357121 )
Catalog No. M18548 CAS No. 433967-28-3
VU0357121, a positive allosteric modulator of mGlu5 (EC50: 33 nM), is inactive or very weakly antagonizing at other mGlu receptor subtypes.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 49 | In Stock |
|
10MG | 78 | In Stock |
|
25MG | 167 | In Stock |
|
50MG | 332 | In Stock |
|
100MG | 500 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVU 0357121
-
NoteResearch use only, not for human use.
-
Brief DescriptionVU0357121, a positive allosteric modulator of mGlu5 (EC50: 33 nM), is inactive or very weakly antagonizing at other mGlu receptor subtypes.
-
DescriptionVU0357121 is a positive allosteric modulator of mGlu5 receptors (EC50 = 33 nM). Mutagenesis studies indicate that VU0357121 and related analogues bind to a yet uncharacterized allosteric site on mGlu(5), distinct from CPPHA, yet share a functional interaction with the MPEP site.
-
SynonymsVU-0357121, VU0357121, VU 0357121
-
PathwayOthers
-
TargetOther Targets
-
RecptormGluR5
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number433967-28-3
-
Formula Weight305.32
-
Molecular FormulaC17H17F2NO2
-
Purity98%
-
SolubilityDMSO : ≥ 50 mg/mL; 163.76 mM
-
SMILESCCCCOc1ccc(cc1)C(=O)Nc1c(cc(cc1)F)F
-
Chemical Name4-Butoxy-N-(2,4-difluorophenyl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hammond AS, et al. ACS Chem Neurosci, 2010, 1(10), 702-716.
molnova catalog
related products
-
BISMUTH SUBGALLATE
Bismuth subgallate is an astringent and antiseptic and is applied to skin diseases such as eczema.
-
Keratin hydrolyzed
Keratin hydrolyzed is a processed form of keratin that allows it to penetrate the hair cuticle.
-
Icotinib Hydrochlori...
Icotinib Hydrochloride is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity.